Aussie committee targets Apple over payment systems
An Australian parliamentary committee recommends an ACCC inquiry into Apple (NASDAQ:AAPL) over its payment network restrictions.
An Australian parliamentary committee recommends an ACCC inquiry into Apple (NASDAQ:AAPL) over its payment network restrictions.
QXO (NYSE:QXO) said its stockholders approved the issuance of shares needed to complete its acquisition of TopBuild (NYSE:BLD), alongside separate approval from TopBuild shareholders for the merger agreement.
Hormel Foods (NYSE:HRL) entered a definitive agreement to sell its Brazilian operations, which operate under the CERATTI brand, to Zanchetta Alimentos LTDA.
The Clarity Act has entered a pivotal two-week period that could see the bill submitted to the US Senate for a vote as early as the end of July.
Genco Shipping & Trading (NYSE:GNK) said its board has unanimously rejected Diana Shipping’s extended unsolicited $24.80 per-share cash tender offer, saying it undervalues the company.
Air T (NASDAQ:AIRT) reported fiscal 2026 revenue of $327.1 million, compared with $291.5 million a year earlier, reflecting 12% growth that included contributions from its Rex acquisition.
Strategy (NASDAQ:MSTR) has launched a "Digital Credit Capital Framework," approving a programme that allows the firm to sell up to US$1.25 billion in Bitcoin (CRYPTO:BTC) to fund cash reserves, service preferred stock dividends on its Stretch (STRC) product, or repurchase common stock at management's discretion.
Gilat Satellite Networks (NASDAQ:GILT) said it secured $43 million in new orders for its Sidewinder electronically steered antenna (ESA) terminals from a major in-flight connectivity service provider.
REGENXBIO (NASDAQ:RGNX) said it has dosed the first patient in the Phase IIb/III NAAVIGATE trial evaluating surabgene lomparvovec in diabetic retinopathy using suprachoroidal delivery.
Satellos Bioscience (NASDAQ:MSLE) said the U.S. Food and Drug Administration has granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy